Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
529 people get IBIO articles and Market Currents by email alert.
Get email alerts on IBIO »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
There are no Transcripts on IBIO.
-
PR Newswire (Jun 10, 2013)
-
PR Newswire (May 29, 2013)
-
PR Newswire (May 22, 2013)
-
PR Newswire (Apr 29, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 19, 2013)
-
PR Newswire (Feb 13, 2013)
-
PR Newswire (Feb 1, 2013)
-
PR Newswire (Dec 21, 2012)
IBIO vs. ETF Alternatives
Company Description
Currently, there's no company description for IBIO.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 10, 11:04 AM iBio (IBIO +18%) says that one of its antibody patents for treating anthrax has been allowed in China. The patent covers a human monoclonal antibody specifically recognizing the cell binding protein known as protective antigen of Bacillus anthracis, the bacteria causing anthrax. The antibody, produced with the use of IBIO's iBioLaunch platform technology, prevented death in 100% of animals given an otherwise lethal doses of anthrax spores. Comment! [Healthcare, On the Move]
- Wednesday, May 22, 9:45 AM IBio (IBIO +23.7%) soars after saying its platform was used in the production of a vaccine candidate for the new avian flu. (PR) Comment! [Healthcare, On the Move]
-
Thursday, July 26, 2012, 9:12 AM
Premarket gainers: GENE +33%. PSDV +24%. IBIO +21%. S +18%. WDC +17%. AKAM +16%. PCS +14%. TEX +13%. FTNT +13%. STX +11%. WFM +11%. GNC +8%. UN +7%. CROX +7%. BBVA +7%. PHM +7%. SVU +6%. SAN +6%. PSTI +6%. EQIX +6%. ABB +6%. IOC +6%. AEM +6%. FTE +6%. MRVL +6%. NOK +5%. OVTI +5%.
Losers: ZNGA -40%. NG -29%. STRA -17%. GLUU -8%. IPG -6%. ESI -7%. GRPN -6%. FB -6%. ALU -6%. STB -6%. ABX -5%. LVS -5%. 1 Comment [On the Move] - Friday, January 27, 2012, 9:55 AM IBio (IBIO +7.9%) says the NYSE Amex confirmed positive resolution of the biotech company's listing deficiency. In November, the exchange indicated its review of iBio's Form 10-K for the fiscal year ended June 20, 2011 showed the company was not in compliance with Section 1003(1)(iv). (submitted by M.E. Garza) Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.